Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:GPHNYSEMKT:IGCNYSE:OGNNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPHGraphite OneC$0.81C$0.93C$0.55▼C$1.07C$82.02M1.0260,654 shs120,252 shsIGCIGC Pharma$0.30-6.8%$0.30$0.25▼$0.62$24.16M1.45351,382 shs214,616 shsOGNOrganon & Co.$9.60+1.6%$13.46$9.18▼$23.10$2.50B0.732.90 million shs13.58 million shsPHARPharming Group$9.02+3.1%$8.43$6.65▼$11.07$613.57M-0.086,440 shs3,432 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPHGraphite One0.00%-11.96%-4.71%-19.80%+14.08%IGCIGC Pharma-0.65%+2.36%+5.19%-4.70%+30,399,900.00%OGNOrganon & Co.+1.69%-21.38%-34.87%-38.40%-49.04%PHARPharming Group+1.57%+6.11%+8.40%+2.96%-13.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.2629 of 5 stars3.50.00.00.00.01.70.0OGNOrganon & Co.4.7313 of 5 stars3.01.03.33.73.11.73.1PHARPharming Group2.755 of 5 stars3.55.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,174.67% UpsideOGNOrganon & Co. 2.00Hold$19.67104.86% UpsidePHARPharming Group 3.00Buy$30.00232.63% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, OGN, GPH, and IGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.003/14/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/6/2025IGCIGC PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.502/24/2025IGCIGC PharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $4.252/14/2025OGNOrganon & Co.BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.002/14/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M19.60N/AN/A$0.08 per share3.80OGNOrganon & Co.$6.40B0.39$3.08 per share3.12($0.27) per share-35.56PHARPharming Group$297.20M2.06$0.10 per share91.82$3.26 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AOGNOrganon & Co.$864M$3.332.882.570.9013.49%431.62%8.03%N/APHARPharming Group-$10.55M-$0.17N/A300.63N/A-6.09%-7.65%-3.82%5/6/2025 (Estimated)Latest PHAR, OGN, GPH, and IGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$1.1211.67%+25.99%33.63%N/APHARPharming GroupN/AN/AN/AN/AN/ALatest PHAR, OGN, GPH, and IGC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/20252/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98OGNOrganon & Co.17.731.701.21PHARPharming Group0.413.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPHGraphite One0.07%IGCIGC Pharma3.87%OGNOrganon & Co.77.43%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipGPHGraphite One28.81%IGCIGC Pharma31.48%OGNOrganon & Co.1.40%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionablePHARPharming Group28068.03 million66.62 millionNot OptionablePHAR, OGN, GPH, and IGC HeadlinesRecent News About These CompaniesPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive DirectorApril 30 at 3:37 PM | finance.yahoo.comPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - What's Next?April 30 at 1:08 PM | marketbeat.comPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of ...April 30 at 12:58 PM | gurufocus.comShort Interest in Pharming Group (NASDAQ:PHAR) Declines By 36.0%April 30 at 4:09 AM | marketbeat.comPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical ...April 25, 2025 | gurufocus.comPharming Group to Present Key Findings at Clinical Immunology Society MeetingApril 25, 2025 | tipranks.comPharming receives positive recommendation from NICE for Joenja®?(leniolisib) as a treatment for APDSApril 24, 2025 | tmcnet.comPharming receives positive recommendation from NICE for Joenja to treat APDS in adult and paediatric patients 12 years of age and olderApril 24, 2025 | pharmabiz.comPharming Group to report first quarter 2025 financial results on May 8 | PHARM Stock NewsApril 24, 2025 | gurufocus.comPharming Group to report first quarter 2025 financial results on May 8 | PHARM Stock NewsApril 24, 2025 | gurufocus.comPharming receives positive recommendation from NICE for Joenja® (leniolisib) as a treatment for APDSApril 23, 2025 | manilatimes.netPharming Group (PHAR) Receives NICE Approval for Joenja in England and Wales | PHAR Stock NewsApril 23, 2025 | gurufocus.comPharming Group’s Joenja® Receives NICE Recommendation for APDS TreatmentApril 23, 2025 | tipranks.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What HappenedApril 23, 2025 | marketbeat.comPharming Group’s Strategic Expansion and NICE Endorsement Drive Buy RatingApril 23, 2025 | tipranks.comPharming Group (NASDAQ:PHAR) Shares Up 4.3% - Should You Buy?April 18, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Short Interest Down 56.9% in MarchApril 18, 2025 | marketbeat.comEuropean Opportunities: 3 Penny Stocks With Market Caps Larger Than €10MApril 15, 2025 | finance.yahoo.comPharming Group (NASDAQ:PHAR) Trading 10.3% Higher - Here's What HappenedApril 9, 2025 | marketbeat.comPharming price target lowered to EUR 2 from EUR 2.15 at RBC CapitalApril 8, 2025 | markets.businessinsider.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's WhyApril 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.3 Biopharmaceutical Stocks Bucking the Sell-OffBy Nathan Reiff | April 10, 2025View 3 Biopharmaceutical Stocks Bucking the Sell-OffPHAR, OGN, GPH, and IGC Company DescriptionsGraphite One CVE:GPHC$0.81 0.00 (0.00%) As of 05/2/2025 03:55 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.30 -0.02 (-6.78%) Closing price 05/2/2025 03:58 PM EasternExtended Trading$0.30 +0.00 (+0.33%) As of 05/2/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Organon & Co. NYSE:OGN$9.60 +0.15 (+1.59%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$9.56 -0.04 (-0.36%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Pharming Group NASDAQ:PHAR$9.02 +0.27 (+3.07%) Closing price 05/2/2025 03:52 PM EasternExtended Trading$9.02 +0.00 (+0.01%) As of 05/2/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
